Literature DB >> 1616956

Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53.

M Montenarh1.   

Abstract

The cellular phosphoprotein p53 was initially discovered in a variety of in vitro transformed and tumor-derived cell lines. Later on, p53 was also found in normal, nontransformed cells albeit at very low levels. Inhibition of p53 functions by microinjection of anti-p53 antibodies prevented quiescent cells from reentering the cell cycle after serum stimulation, indicating that p53 might somehow be involved in the regulation of cell proliferation. After detection of p53-specific mRNAs, the gene was discovered in diverse species ranging from fish and frog to man. Knowing the p53 DNA sequence, it became clear that mutant forms of p53 had immortalizing and, in cooperation with other oncogenes, transforming activities. On the other hand, wild-type p53 could suppress oncogene-mediated transformation. It seems clear now that wild-type p53 is a tumor suppressor. Moreover, analysis of p53 from many types of human tumors indicates that the p53 gene is a very frequent target for mutational alterations. Because the biochemical consequences of these alterations are not yet clear, it is not understood yet on the molecular level how p53 can act as an oncogenic protein, on one hand, and as a growth-suppressor protein on the other hand. Therefore, the present review aims to summarize the biochemical and immunological properties of p53 and to address some biological activities of p53 in order to allow more insight into how p53 might be regulated within the cell or how p53 might regulate cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616956

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  10 in total

1.  Immunohistochemical studies of sensory neurons in rat olfactory epithelium.

Authors:  C C Huang; K Chen; T Y Huang
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

2.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 3.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

4.  p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.

Authors:  T Günther; R Schneider-Stock; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts.

Authors:  P Muganda; O Mendoza; J Hernandez; Q Qian
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations.

Authors:  A Y Matsushima; E Cesarman; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

7.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

8.  Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.

Authors:  A Zauberman; Y Barak; N Ragimov; N Levy; M Oren
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

9.  Apoptosis Induction, Cell Cycle Arrest and Anti-Cancer Potential of Tamoxifen-Curcumin Loaded Niosomes Against MCF-7 Cancer Cells.

Authors:  Mahdi Fatemizadeh; Farzaneh Tafvizi; Farzaneh Shamsi; Sahar Amiri; Afsaneh Farajzadeh; Iman Akbarzadeh
Journal:  Iran J Pathol       Date:  2022-02-28

10.  Expressions of cell cycle regulators in human colorectal cancer cell lines.

Authors:  O Tominaga; M E Nita; H Nagawa; S Fujii; T Tsuruo; T Muto
Journal:  Jpn J Cancer Res       Date:  1997-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.